Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction.

Barra S, Almeida I, Caetano F, Providência R, Paiva L, Dinis P, Leitão Marques A.

Thromb Res. 2013 Aug;132(2):293-9. doi: 10.1016/j.thromres.2013.06.025. Epub 2013 Aug 5.

PMID:
23928474
2.

Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS.

Barra S, Providência R, Paiva L, Almeida I, Caetano F, Dinis P, Leitão Marques A.

J Atr Fibrillation. 2013 Dec 31;6(4):897. doi: 10.4022/jafib.897. eCollection 2013 Dec.

3.

Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.

Tu HT, Campbell BC, Meretoja A, Churilov L, Lees KR, Donnan GA, Davis SM.

Cerebrovasc Dis. 2013;36(4):273-80. doi: 10.1159/000353670. Epub 2013 Oct 16.

PMID:
24135809
4.

[Prediction of cerebrovascular event risk following myocardial infarction].

Barra S, Providência R, Lourenço Gomes P, Silva J, Seca L, Nascimento J, Leitão-Marques AM.

Rev Port Cardiol. 2011 Jul;30(7-8):655-63. doi: 10.1016/S0870-2551(11)70004-X. Portuguese.

PMID:
22005309
5.

Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation.

Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.

Int J Cardiol. 2013 Sep 30;168(2):904-9. doi: 10.1016/j.ijcard.2012.10.052. Epub 2012 Nov 17.

PMID:
23167998
6.

ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction.

Barra S, Providência R, Paiva L, Caetano F, Almeida I, Gomes P, Marques AL.

Eur Heart J Acute Cardiovasc Care. 2012 Dec;1(4):320-36. doi: 10.1177/2048872612466536.

7.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.

PMID:
22246443
8.

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY.

Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3.

PMID:
22473219
9.

Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?

Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, Vicente V, Lip GY.

Thromb Haemost. 2013 May;109(5):956-60. doi: 10.1160/TH13-01-0054. Epub 2013 Mar 21.

PMID:
23572113
10.

Pre-admission CHADS2, CHA2DS2-VASc, and R2CHADS2 Scores on Severity and Functional Outcome in Acute Ischemic Stroke with Atrial Fibrillation.

Tanaka K, Yamada T, Torii T, Furuta K, Matsumoto S, Yoshimura T, Takase K, Wakata Y, Nakashima N, Kira J, Murai H.

J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1629-35. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.036. Epub 2015 Apr 20.

PMID:
25906940
11.

The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation.

Chan YH, Yiu KH, Lau KK, Yiu YF, Li SW, Lam TH, Lau CP, Siu CW, Tse HF.

Atherosclerosis. 2014 Dec;237(2):504-13. doi: 10.1016/j.atherosclerosis.2014.08.026. Epub 2014 Aug 30.

PMID:
25463082
12.

CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, Nyman K, Niemelä M, Lip GY, Airaksinen KE.

Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007. Epub 2014 Jan 11.

PMID:
24461143
13.

Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation.

Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA.

J Am Coll Cardiol. 2014 Oct 21;64(16):1658-65. doi: 10.1016/j.jacc.2014.06.1203.

14.

Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke.

Lau KK, Chan PH, Yiu KH, Chan YH, Liu S, Chan KH, Yeung CY, Li SW, Tse HF, Siu CW.

Cardiol J. 2014;21(5):474-83. doi: 10.5603/CJ.a2014.0034. Epub 2014 May 20.

PMID:
24846512
15.

Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome.

Widera C, Pencina MJ, Meisner A, Kempf T, Bethmann K, Marquardt I, Katus HA, Giannitsis E, Wollert KC.

Eur Heart J. 2012 May;33(9):1095-104. doi: 10.1093/eurheartj/ehr444. Epub 2011 Dec 23.

16.

Improving risk stratification in non-ST-segment elevation myocardial infarction with combined assessment of GRACE and CRUSADE risk scores.

Paiva L, Providência R, Barra SN, Dinis P, Faustino AC, Costa M, Gonçalves L.

Arch Cardiovasc Dis. 2014 Dec;107(12):681-9. doi: 10.1016/j.acvd.2014.06.008. Epub 2014 Sep 11.

17.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators..

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

18.

Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.

Apostolakis S, Lane DA, Buller H, Lip GY.

Thromb Haemost. 2013 Nov;110(5):1074-9. doi: 10.1160/TH13-07-0552. Epub 2013 Sep 19.

PMID:
24048467
19.

Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY.

J Am Coll Cardiol. 2013 May 21;61(20):2079-87. doi: 10.1016/j.jacc.2013.02.035. Epub 2013 Mar 21.

20.

Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents.

Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H, Carrel T, Moschovitis A, Stortecky S, Wenaweser P, Stefanini GG, Räber L, Meier B, Jüni P, Windecker S.

EuroIntervention. 2013 Jan 22;8(9):1061-71. doi: 10.4244/EIJV8I9A163.

Supplemental Content

Support Center